Summary
The development of animal models of Parkinson’s disease is of great importance in order to test substitutive or neuroprotective strategies for Parkinson’s disease. Such models should reproduce the main characteristics of the disease, such as a selective lesion of dopaminergic neurons that evolves over time and the presence of neuronal inclusions known as Lewy bodies. Optimally, such models should also reproduce the lesion of non-dopaminergic neurons observed in a great majority of patients with Parkinson’s disease. From a behavioral point of view, a parkinsonian syndrome should be observed, ideally with akinesia, rigidity and rest tremor. These symptoms should be alleviated by dopamine replacement therapy, which may in turn lead to side effects such as dyskinesia. In this review, we analyze the main characteristics of experimental models of Parkinson’s disease induced by neurotoxic compounds such as 6-hydroxydopamine, MPTP and rotenone. We show that, whereas MPTP and 6-hydroxydopamine induce a selective loss of catecholaminergic neurons that in most cases evolves over a short period of time, rotenone infusion by osmotic pumps can induce a chronically progressive degeneration of dopaminergic neurons and also of non-dopaminergic neurons in both the basal ganglia and the brainstem.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Adams RD, van Bogaert L, van der Eecken H (1961) Dégénérescences nigro-striées et cérébello-nigro-striées. Psychiatria Neurol 142: 219–259
Arai N, Misugi K, Goshima Y, Misu Y (1990) Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res 515: 57–63
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455
Betarbet R, Sherer TB, Mac Kenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3: 1301–1306
Bezard E, Imbert C, Deloire X, Bioulac B, Gross CE (1997) A chronic MPTP model reproducing the slow evolution of Parkinson’s disease: evolution of motor symptoms in the monkey. Brain Res 766: 107–112
Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci 80: 4546–4550
Chia LG, Ni DR, Cheng LJ, Kuo JS, Cheng FC, Dryhurst G (1996) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice. Neurosci Lett 218: 67–71
Colotla VA, Flores E, Oscos A, Meneses A, Tapia R (1990) Effects of MPTP on locomotor activity in mice. Neurotoxicol Teratol 12: 405–407
Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV (1991) Cognitive impairment in early, untreated Parkinson’s disease and its relationship to motor disability. Brain 114: 2095–2122
Daniel SE, de Bruin VMS, Lees AJ (1995) The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 118: 759–770
Degryse AD, Colpaert FC (1986) Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old java monkey [Macaca cynamolgus fascicularis (raffles)]. Brain Res Bull 16: 561–571
Doudet D, Gross C, Lebrun-Grandié P, Bioulac B (1985) MPTP primate model of Parkinson’s disease: a mechanographic and electromyographic study. Brain Res 335: 194–199
Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci 98: 14669–14674
Fearnley JM, Lees AJ (1990) Striatonigral degeneration. A clinicopathological study. Brain 113: 1823–1842
Ferrante RJ, Schulz JB, Kowall NW, Beal MF (1997) Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753: 157–162
Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55: 259–272
Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20: 449–455
Forno LS, Langston JW, DeLanney LE, Irwin I (1988) An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res 448: 150–157
Fredriksson A, Eriksson P, Archer T (1997) MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN). J Neural Transm 104: 579–592
Gao ZG, Cui WY, Zhang HT, Liu CG (1998) Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice. Pharmacol Res 38: 101–106
Hantraye PH, Khalili-Varastet M, Peschanski M, Mazière M (1990) MPTP: mécanismes biologiques et limites d’un modèle expérimental de la maladie de Parkinson. Circul Metabol Cerveau 7: 15–19
Hapdey C, Parain K, Rousselet E, Marchand V, Dumery B, Hirsch EC (2002) Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine parkinsonian toxin (submitted)
Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224: 1451–1453
Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334: 345–348
Hirsch EC, Hunot S, Damier P, Faucheux B (1998) Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? Ann Neurol 44[3 Suppl 1]: S115–S120
Hirsch EC, Orieux G, Muriel MP, Francois C, Féger J (2003) Non dopaminergic neurons in Parkinson’s disease. Adv Neurol 91: 29–37
Höglinger GU, Feger J, Prigent A, Parain K, Champy P, Ruberg M, Oertel W, Hirsch EC (2003) Chronic systemic inhibition of mitochondrial complex 1 induces a hypokinetic syndrome in rats with degeneration of multiple neuronal systems. J Neurochem 84: 491–502
Hornykiewicz O (1963) Die topische Lokalization und das Verhalten von Noradrenalin und Dopamine (3-hydroxytyramin) in der Substantia nigra des normalen und parkinsonkranken Menschen. Wien Klin Wochenschr 75: 309–321
Hornykiewicz O (1975) Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser 13–21
Hulley P, Hartikka J, Abdel’Al S, Engels P, Buerki HR, Wiederhold KH, Muller T, Kelly P, Lowe D, Lubbert H (1995) Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur J Neurosci 7: 2431–2340
Hoskins JA, Davis LJ (1989) The acute effect on levels of catecholamines and metabolites in brain, of a single dose of MPTP in 8 strains of mice. Neuropharmacology 28:1389–1397
Hu SC, Chang FW, Sung YJ, Hsu WM, Lee EH (1991) Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice. J Pharmacol Exp Ther 259: 1379–1387
Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4: 257–269
Janson AM, Moller A (1993) Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitranssection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 57: 931–941
Javoy-Agid F, Agid Y (1980) Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology 30: 1326–1330
Jellinger KA (1991) Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14: 153–197
Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson’s disease. Mov Disord 13[Suppl 1]: 24–34
Jenner P, Rupniak NMJ, Rose S, Kelly E, Kilpatrick G, Lees A, Marsden CD (1990) 1-methyl-4-phényl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50: 85–90
Jonsson G, Sundstrom E, Mefford I, Olson L, Johnson S, Freedman R, Hoffer B (1985) Electrophysiological and neurochemical correlates of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. Naunyn Schmiedebergs Arch Pharmacol 331: 1–6
Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 156: 50–61
Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. N Engl J Med 339: 1044–1053
Lang AE, Lozano AM (1998) Parkinson’s disease. Second of two parts. N Engl J Med 339: 1130–1143
Langston JW, Ballard PA, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106: 257–270
Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Med 5: 1403–1409
Malone MA, Kershner JR, Swanson JM (1994) Hemispheric processing and methylpheni-date effects in attention-deficit hyperactivity disorder. J Child Neurol 9: 181–189
Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD (1992) Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson’s disease. Brain 115: 333–342
McKeith IG (2000) Clinical Lewy body syndromes. Ann NY Acad Sci 920: 1–8
McNeill TH, Brown SA, Rafols JA, Shoulson I (1988) Atrophy of medium spiny I striatal dendrites in advanced Parkinson’s disease. Brain Res 455: 148–152
Mitra N, Mohanakumar KP, Ganguly DK (1992) Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res Bull 28: 355–364
Niéoullon A, Chéramy A, Glowinski J (1977) Interdependence of the nigrostriatal dopaminergic systems on the two side of the brain in the cat. Science 198: 416–418
Olanow W, Schapira AH, Rascol O (2000) Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends Neurosci 23[Suppl 10]: S117–S126
Parain K, Marchand V, Dumery B, Hirsch EC (2001) Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res 890: 347–350
Périer C, Agid Y, Hirsch EC, Féger J (2000) Ipsi-and contralateral subthalamic activity after unilateral dopaminergic lesion. NeuroReport 11: 3275–3278
Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS (2001) Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106: 589–601
Pift C, Schingnitz G, Hornykiewicz O (1991) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44: 591–605
Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38: 277–301
Rousselet E, Joubert C, Callebert J, Parain K, Tremblay L, Orieux G, Perez-Diaz F, Launay JM, Cohen-Salmon C, Hirsch EC (2002) Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons or dose of parkinsonian toxin MPTP in mice (submitted)
Salin P, Hajji MD, Kerkerian-Legoff L (1996) Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on the enkephalin expression in rat basal ganglia. Eur J Neurosci 8: 1746–1757
Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59: 401–415
Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet i: 1269
Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54: 823–827
Schneider JS (1990) Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res 534: 25–36
Schneider JS, Pope-Coleman A (1995) Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 4(3): 245–255
Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 64: 936–939
Sharma N, McLean PJ, Kawamata H, Irizarry MC, Hyman BT (2001) α-Synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies. Acta Neuropathol (Berl) 102: 329–334
Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30: 171–182
Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 293: 263–269
Stam CJ, de Bruin JP, van Haelst AM, van der Gugten J, Kalsbeek A (1989) Influence of the mesocortical dopaminergic system on activity, food hoarding, social-agonistic behavior, and spatial delayed alternation in male rats. Behav Neurosci 103: 24–35
Steele JC, Richardson JC, Olszewski J (1964) Progressive Supranuclear Palsy. A heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10: 333–359
Sundstrom E, Stromberg I, Tsutsumi T, Olson L, Jonsson G (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405: 26–38
Tanila H, Bjorklund M, Riekkinen PJ (1998) Cognitive changes in mice following moderate MPTP exposure. Brain Res Bull 45: 577–582
Taylor AE, Saint-Cyr JA, Lang AE (1986) Frontal lobe dysfunction in Parkinson’s disease. The cortical focus of neostriatal outflow. Brain 109: 845–883
Teismann P, Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease. Synapse 39: 167–174
Ungerstedt U (1968) 6-hydroxydopamine-induced degeneration of central monoamine neurons. Eur J Pharmacol 5: 107–110
Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Proc Natl Acad Sci 98: 2837–2842
Willis GL, Donnan GA (1987) Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 402: 269–274
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Wien
About this paper
Cite this paper
Hirsch, E.C. et al. (2003). Animal models of Parkinson’s disease in rodents induced by toxins: an update. In: Horowski, R., et al. Advances in Research on Neurodegeneration. Journal of Neural Transmission. Supplementa, vol 65. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0643-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0643-3_6
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83907-2
Online ISBN: 978-3-7091-0643-3
eBook Packages: Springer Book Archive